This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Groot, K Articles by Gross, W L Search for Related Content PubMed PubMed Citation Articles by de Groot, K Articles by Gross, W L Social Bookmarking                   What's this?

Wegener's granulomatosis: disease course, assessment of activity and extent and treatment

W L Gross

Medizinische Universität Luëbeck, Abteilung Klinische Rheumatologie, Oskar-Alexander-Straße 26, D-24572 Bad Bramstedt, Germany

Wegener's granulomatosis (WG) belongs to the group of necrotizing primary systemic vasculitides of unknown etiology, that are associated with anti-neutrophil cytoplasmic antibodies. The pathological hallmark of WG is the coexistence of vasculitis and granuloma. Due to more sensitive diagnostic instruments, especially ANCA testing, the incidence of diagnosis of WG has risen in the past ten years. Although the precise pathophysiology is not understood yet, there is ample evidence that ANCA, which can lead to cytotoxic reactions in the vascular texture, play a major role, possibly promoted by a dysbalance in the anti-idiotypic network. The clinical disease course is typically two-phasic, beginning with a granulomatous inflammation of the upper respiratory tract, that usually is followed by a generalized vasculitic phase, that can range from mild organ dysfuntion to lifethreatening multi-organ failure. Consequently, diagnostic procedures, patients' assessment and therapeutic regimens need to be individualized, adapted to stage and activity of the disease as well as standardized.

Key Words: Wegener's granulomatosis • PR3-ANCA • disease activity and extent • stage adapted therapy

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. C. Finley Jr, D. C. Bloom, and J. K. Thiringer Wegener Granulomatosis Presenting as an Infiltrative Retropharyngeal Mass With Syncope and Hypoglossal Paresis Arch Otolaryngol Head Neck Surg, March 1, 2004; 130(3): 361 - 365. [Abstract] [Full Text] [PDF]

				W. Koldingsnes and H. Nossent Predictors of survival and organ damage in Wegener's granulomatosis Rheumatology, May 1, 2002; 41(5): 572 - 581. [Abstract] [Full Text] [PDF]

				K. Hattar, U. Grandel, A. Bickenbach, A. Schwarting, W.-J. Mayet, J. Bux, S. Jessen, C. Fischer, W. Seeger, F. Grimminger, et al. Interaction of Antibodies to Proteinase 3 (Classic Anti-Neutrophil Cytoplasmic Antibody) with Human Renal Tubular Epithelial Cells: Impact on Signaling Events and Inflammatory Mediator Generation J. Immunol., March 15, 2002; 168(6): 3057 - 3064. [Abstract] [Full Text] [PDF]

				P Lamprecht, F Moosig, A Gause, K Herlyn, E Csernok, H Hansen, and W L Gross Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis Ann Rheum Dis, April 1, 2001; 60(4): 385 - 390. [Abstract] [Full Text] [PDF]

				U. Schonermarck, P. Lamprecht, E. Csernok, and W. L. Gross Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA Rheumatology, February 1, 2001; 40(2): 178 - 184. [Abstract] [Full Text] [PDF]

				W. L. Gross, A. Trabandt, and E. Reinhold-Keller Diagnosis and evaluation of vasculitis Rheumatology, March 1, 2000; 39(3): 245 - 252. [Full Text] [PDF]

				J. M. Knight, M. J. Hayduk, D.-J. Summerlin, and G. W. Mirowski "Strawberry" Gingival Hyperplasia: A Pathognomonic Mucocutaneous Finding in Wegener Granulomatosis Arch Dermatol, February 1, 2000; 136(2): 171 - 173. [Full Text] [PDF]